The rapid deployment of healthcare technology has been one of the most commented features of the NHS’ response to the coronavirus pandemic. Yet a significant minority of patients cannot benefit from new, digital services; and risk being overlooked in the rush to go ‘digital first’ in a post-Covid reset. So what can be done to get digital inclusion onto the digital health agenda? 
New York-Tel Aviv based digital health company, AEYE Health, has developed an AI-based retinal screening system that provides analysis and diagnostic results within 60 seconds.
Retinal diseases such as diabetic retinopathy (DR), glaucoma, macular degeneration and hypertensive retinopathy are becoming a pandemic. Over a billion people worldwide, and over 75 million people in the US, are at high risk for loss of sight and require an annual retinal check.
A consortium of NHS trusts around the south coast of England has signed its second deal this year with imaging technology provider Sectra, in a move that is expected to advance how hospitals share and access important diagnostic imaging. A new shared multimedia archive will also allow the trusts to accelerate ambitions for initiatives including artificial intelligence. 
An early warning system that helps busy doctors, nurses and other healthcare professionals to quickly identify when patients are at risk of deterioration is to be deployed across hospitals and community settings throughout Lanarkshire. 
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including a patient-preferred design without compromising battery longevity and MRI compatibility. 